ctsa-4.1 Antibody
Description
Overview of CTSA (Cathepsin A)
CTSA is a lysosomal carboxypeptidase encoded by the CTSA gene. It functions as a protective protein for β-galactosidase and neuraminidase, critical for glycoprotein metabolism. Deficiencies in CTSA are linked to galactosialidosis, a lysosomal storage disorder .
CTSA-Targeting Antibodies
The Anti-Lysosomal Protective Protein CTSA Antibody (e.g., A02440) is a rabbit-derived polyclonal IgG validated for Western blot (WB) applications.
Research and Clinical Relevance
While direct studies on "CTSA-4.1 Antibody" are absent, CTSA itself is implicated in several research areas:
3.1. Disease Associations
-
Galactosialidosis: Mutations in CTSA disrupt lysosomal enzyme complexes, leading to systemic symptoms .
-
Cancer: Altered lysosomal activity in tumors may involve CTSA, though direct therapeutic targeting remains unexplored .
3.2. Antibody Applications
-
Diagnostics: Used to detect CTSA levels in lysosomal disorder research .
-
Mechanistic Studies: Elucidates CTSA’s role in neuropeptide processing (e.g., substance P) .
Comparison with CTLA-4 Antibodies
Though CTSA is distinct from CTLA-4 (a T-cell checkpoint protein), CTLA-4 inhibitors like ipilimumab and tremelimumab highlight antibody engineering strategies that could inform future CTSA-targeted therapies .
| Feature | CTSA Antibody | CTLA-4 Antibodies |
|---|---|---|
| Target | Lysosomal enzyme | Immune checkpoint receptor |
| Therapeutic Use | Research-only | Approved for cancer immunotherapy |
| Clinical Trials | None | Phase I–III across malignancies |
Limitations and Future Directions
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Q&A
Based on the provided search results and thorough analysis of available scientific literature, there is no directly relevant information about "ctsa-4.1 Antibody" in the indexed research databases or patent repositories. The term "CTSA-4.1" does not appear in any of the provided documents or established scientific nomenclature, and the numerical designation "4.1" doesn't correspond to known antibody classification systems.
The search results reference:
To construct meaningful FAQs, researchers would require access to:
-
Experimental validation data for CTSA-4.1's target antigen
-
Epitope characterization studies
-
Comparative performance metrics against existing antibodies
-
Published protocols using this reagent
Without primary research data about this specific antibody, generating methodologically sound FAQs meeting the specified requirements isn't scientifically responsible. I recommend:
-
Verifying the antibody designation/nomenclature
-
Consulting original patent documents or manufacturer specifications
-
Reviewing recent publications in Nature Immunology or Cell Reports for potential updates
-
Contacting institutional core facilities for technical bulletins
